Sélectionner la langue
TSLP R
TSLP R Informations sur la molécule
| Nom anglais | Thymic stromal lymphopoietin | Nombre de médicaments commercialisés | 1 |
| Nombre de médicaments cliniques | 28 | Alias de la cible | Thymic stromal lymphopoietin，TSLP |
| Phase de R&D la plus avancée | Approved | ||
| Nom anglais | Thymic stromal lymphopoietin |
| Alias de la cible | Thymic stromal lymphopoietin，TSLP |
| Nombre de médicaments commercialisés | 1 |
| Nombre de médicaments cliniques | 28 |
| Phase de R&D la plus avancée | Approved |
TSLP R Liste de produits
- Attribut
Protein (3)
- Bibliothèque de produits
En ligne (3)
- Espèces
Human (2)Cynomolgus (1)
- Étiquette
Fc Tag (1)Fc Tag & Avi Tag (1)His Tag (1)
- Marqueur
Unconjugated (2)Biotin-labeled (1)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
 Human | HEK293 | Human TSLP R Protein, Fc Tag (MALS verified) |  |  |  |  Ajouter au panier | |
| Human | HEK293 | Biotinylated Human TSLP R Protein, Fc,Avitag™ |  | | | Ajouter au panier | |
 Cynomolgus | HEK293 | Cynomolgus TSLP R Protein, His Tag (MALS verified) |  | | | Ajouter au panier |
Quantité totale3
- 1
TSLP RContexte de la molécule
The encoded protein is a receptor for thymic stromal lymphopoietin (TSLP),TSLP binding to a heterodimeric receptor complex composed of IL-7Ralpha and the TSLP receptor (TSLPR) activate STAT3, STAT5, and JAK2 pathways, which plays an important role in the regulation of immune responses to allergens.
TSLP RAlias de la molécule
TSLP R,CRLF2,IL-XR,ILXR,p2RY8,CRLF2 fusion,TSLP receptor,TSLPR,CRL2,CRLF2Y,Cytokine receptor-like 2
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| QL-2302 | QL2302; QL-2302 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Asthma | Details |
| GB-0895 | GB-0895 | Phase 3 Clinical | Generate Biomedicines Inc | Asthma; Immune System Diseases; Pulmonary Disease, Chronic Obstructive | Details |
| Tilrekimig | PF-07275315 | Phase 3 Clinical | Pfizer Inc | Asthma; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive | Details |
| Lunsekimig | SAR-443765 | Phase 3 Clinical | Sanofi | Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis, Atopic; Inflammation; Pulmonary Disease, Chronic Obstructive | Details |
| Bosakitug | TQC-2731; BSI-045B; TQC2731; ATI-045 | Phase 3 Clinical | Biosion Inc | Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis; Dermatitis, Atopic; Eczema; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis | Details |
| SHR-1905 | SHR-1905; AIO-001; GSK-5784283 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis, Atopic; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Diseases; Sinusitis | Details |
| CM-326 | CM-326 | Phase 3 Clinical | Keymed Biosciences Co Ltd | Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis, Atopic; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis | Details |
| QX-008N | QX-008N; QX008N; JKN-2401; JKN2401; SNCA008; SNCA-008 | Phase 3 Clinical | Qyuns Therapeutics Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| Solrikitug | NSI-8226; MK-8226 | Phase 2 Clinical | Merck & Co Inc | Asthma; Dermatitis, Atopic; Eosinophilic Esophagitis; Hypertension; Pulmonary Disease, Chronic Obstructive | Details |
| Ecleralimab | CSJ-117; NOV-14 | Phase 2 Clinical | Novartis Pharma Ag | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| HBM-9378 | HBM-9378; SKB378; SKB-378; A-378; WIN378; WIN-378 | Phase 2 Clinical | Harbour Biomed, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| CM-512 | CM512; CM-512 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Asthma; Bronchiectasis; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Dermatitis, Atopic; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Rhinitis, Allergic; Sinusitis | Details |
| IBI-3002 | IBI3002; IBI-3002 | Phase 2 Clinical | Asthma; Dermatitis, Atopic | Details | |
| MG-ZG122 | MG-ZG122; MGZG122 | Phase 2 Clinical | Shanghai Mabgeek Biotechnology Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| AZD-8630 | AZD-8630; AMG-104 | Phase 2 Clinical | Amgen Inc, Astrazeneca Plc | Asthma | Details |
| TAVO-101 | TAVO-101; TAVO101 | Phase 2 Clinical | Tavotek Biotherapeutics (Hong Kong) Ltd | Dermatitis, Atopic; Hypersensitivity | Details |
| PF-06342674 | RN-168; PF-6342674; PF-06342674; ZB-168 | Phase 1 Clinical | Pfizer Inc | Diabetes Mellitus, Type 1; Multiple Sclerosis | Details |
| APG273 | APG273; APG-273 | Phase 1 Clinical | Apogee Therapeutics Inc | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| HBM-7575 | HBM-7575; SKB575; SKB-575; HBM7575 | Phase 1 Clinical | Harbour Biomed | Dermatitis, Atopic; Inflammation | Details |
| WIN-027 | QX027N; QX-027-N; WIN027; WIN-027 | Phase 1 Clinical | Qyuns Therapeutics Co Ltd | Asthma; Dermatitis, Atopic | Details |
| HB-0056 | HB-0056; HB0056 | Phase 1 Clinical | Shanghai Huaota Biopharmaceutical Co Ltd, Zhejiang Huahai Pharmaceutical Co Ltd | Asthma; Dermatitis, Atopic; Idiopathic Pulmonary Fibrosis; Pulmonary Disease, Chronic Obstructive | Details |
| APG-333 | APG333; APG-333; PR018; PR-018 | Phase 1 Clinical | Apogee Therapeutics Inc | Asthma | Details |
| SAR-444765 | SAR444765; SAR-444765 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| BSI-502 | BSI-502; ATI-052 | Phase 1 Clinical | Biosion Inc | Autoimmune Diseases of the Nervous System; Inflammation | Details |
| CDX-622 | CDX-622 | Phase 1 Clinical | Celldex Therapeutics Inc | Asthma; Fibrosis; Hypersensitivity; Inflammation | Details |
| STSA-1201 | STSA-1201; STSA1201 | Phase 1 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Asthma | Details |
| LQ043H | LQ043H | Phase 1 Clinical | Shanghai Novamab Biopharmaceuticals Co Ltd | Asthma | Details |
| GR2002 | GR2002 | Phase 1 Clinical | Genrix (Shanghai) Biopharmaceutical Co Ltd | Asthma; Dermatitis, Atopic; Nasal Polyps; Sinusitis | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Tezepelumab | MEDI-9929; AMG-157 | Approved | Amgen Inc | Tezspire | United States | Asthma | Astrazeneca Ab | 2021-12-17 | Anaphylaxis; Asthma; Bronchial Diseases; Carcinoma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Dermatitis, Atopic; Eosinophilic Esophagitis; Granulomatosis with Polyangiitis; Hypersensitivity; Hypersensitivity, Immediate; Immune System Diseases; Lung Diseases; Lung Diseases, Obstructive; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Respiratory Hypersensitivity; Respiratory Tract Diseases; Sinusitis | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments commercialisés
- Informations sur les médicaments cliniques
Partager vers :